Bio-Path Holdings, Inc. (BPTH)
OTCMKTS · Delayed Price · Currency is USD
0.1410
+0.0010 (0.71%)
Apr 25, 2025, 2:05 PM EDT

Bio-Path Holdings Company Description

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States.

Its drug delivery and antisense technology is the DNAbilize, a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body’s enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge.

The company’s lead drug candidate is the Prexigebersen (BP1001), which is in phase 2 clinical trial for the treatment of untreated acute myeloid leukemia (AML).

It is also developing BP1001-A, which is in phase 1 clinical trial for treatment of solid tumors, including ovarian, endometrial and pancreatic cancer, as well as in preclinical trial to treat obesity and related metabolic diseases; Liposomal Bcl-2 (BP1002), which is in phase 1 clinical trial to treat refractory/relapsed lymphoma and refractory/relapsed chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003), which is preclinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and AML.

Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

Bio-Path Holdings, Inc.
Bio-Path Holdings logo
Country United States
Founded 2007
Industry Biotechnology
Sector Healthcare
Employees 10
CEO Peter Nielsen

Contact Details

Address:
4710 Bellaire Boulevard
Bellaire, Delaware 77401
United States
Phone 832 742 1357
Website biopathholdings.com

Stock Details

Ticker Symbol BPTH
Exchange OTCMKTS
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
ISIN Number US09057N3008
SIC Code 2836

Key Executives

Name Position
Peter H. Nielsen MBA Co-Founder, Chairman of the Board, Chief Executive Officer, President, Chief Financial Officer and Treasurer
Douglas P. Morris Co-Founder, Director of Investor Relations, Secretary and Director
Michael Hickey M.B.A. Vice President of Clinical Operations
Anthony Price MBA Senior Vice President of Finance, Accounting and Administration
Dr. Ana Tari Ashizawa M.B.A., MBA, Ph.D. Senior Vice President of Research, Development and Clinical Design